Sarepta Therapeutics, Inc. $SRPT Holdings Increased by 683 Capital Management LLC

Key Points

• 683 Capital Management LLC increased its stake in Sarepta Therapeutics by 61.8%, now owning 165,000 shares, which account for approximately 0.7% of its total holdings.
• Sarepta Therapeutics recently reported a 68.4% increase in revenue year-over-year, achieving $611.09 million, and beat earnings estimates with $2.02 per share.
• Analysts have mixed ratings on SRPT, with a consensus target price of $43.50 and a predominance of "Hold" ratings among the analysts covering the stock.

683 Capital Management LLC raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 61.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,000 shares of the biotechnology company's stock after acquiring an additional 63,000 shares during the quarter. Sarepta Therapeutics makes up 0.7% of 683 Capital Management LLC's portfolio, making the stock its 28th biggest position. 683 Capital Management LLC owned 0.17% of Sarepta Therapeutics worth $10,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC boosted its stake in Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after acquiring an additional 285,100 shares during the last quarter. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after acquiring an additional 577,848 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Sarepta Therapeutics by 2.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock valued at $127,512,000 after acquiring an additional 41,408 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Sarepta Therapeutics by 438.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after acquiring an additional 580,123 shares during the last quarter. Finally, Aberdeen Group plc boosted its stake in Sarepta Therapeutics by 42.1% during the 1st quarter. Aberdeen Group plc now owns 650,279 shares of the biotechnology company's stock valued at $41,676,000 after acquiring an additional 192,584 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded up $0.25 during trading hours on Friday, reaching $18.71. The stock had a trading volume of 5,173,257 shares, compared to its average volume of 8,848,577. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $138.81. The firm has a 50-day simple moving average of $17.78 and a 200-day simple moving average of $44.36. The firm has a market capitalization of $1.83 billion, a PE ratio of -21.51 and a beta of 0.49.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. During the same quarter last year, the company earned $0.07 EPS. The company's revenue for the quarter was up 68.4% compared to the same quarter last year. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of recent research reports. Bank of America raised their price target on shares of Sarepta Therapeutics to $17.00 and gave the stock an "underperform" rating in a research report on Wednesday, August 20th. Needham & Company LLC restated an "underperform" rating on shares of Sarepta Therapeutics in a research report on Monday, July 28th. Wells Fargo & Company raised their price target on shares of Sarepta Therapeutics from $48.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Oppenheimer upgraded shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $30.00 to $37.00 in a research report on Tuesday, July 29th. Finally, Wall Street Zen upgraded shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $43.50.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.